Analytical approaches to reporting long-term clinical trial data

Current Medical Research and Opinion

Volumn 24, Issue 7, 2008, Pages 2001-2008

  Papp, Kim A ^a   Fonjallaz, Philippe ^b   Casset Semanaz, Florence ^b   Krueger, James G ^c   Wittkowski, Knut M ^c  

^a PROBITY MEDICAL RESEARCH   (Canada)

^b MERCK SERONO S A   (Switzerland)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Follow up studies; Long term clinical studies; Methodology; Multiple analysis approach; Randomized controlled trials

Indexed keywords

ANALYTIC METHOD; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; DATA ANALYSIS; HYPOTHESIS; INFORMATION PROCESSING; MEDICAL DECISION MAKING; MEDICAL LITERATURE; NOTE; OBSERVATIONAL METHOD; PRACTICE GUIDELINE; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL MODEL;

DATA INTERPRETATION, STATISTICAL; GUIDELINES AS TOPIC; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 47949132809     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802215315     Document Type: Note

References (17)

1. Committee for Proprietary Medicinal Products (CPMP). Points to consider on missing data: the European Agency for the Evaluation of Medicinal Products (EMEA); 2001
2. De Deyn PP, D'Hooge R. Placebos in clinical practice and research. J Med Ethics 1996;22:140-6
3. Fisher LD, Dixon DO, Herson J, et al. Intention-to-treat in clinical trials. In: Peace KE, editor. Statistical issues in drug research and development. New York: Raven Press; 1990
4. Frangakis CE, Rubin DB. Addressing the complications of intention-to-treat analysis in the combined presence of all-or-none treatment non-compliance and subsequent missing outcomes. Biometrika 1999;86:365-79
5. ICH Topic E9: statistical principles for clinical trials. Note for guidance on statistical principles for clinical trials: the European Agency for the Evaluation of Medicinal Products (EMEA); 1998
6. Altman DG, Schulz KF, Moher D, et al. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 2001;134:663-94
7. Mazumdar S, Liu KS, Houck PR, et al. Intent-to-treat analysis for longitudinal clinical trials: coping with the challenge of missing values. J Psychiatr Res 1999;33:87-95
8. Little RJA, Rubin DB. Statistical analysis with missing data, 2nd ed. Chichester: Wiley; 2002
9. Youk AO, Stone RA, Marsh GM. A method for imputing missing data in longitudinal studies. Ann Epidemiol 2004;14:354-61
10. Mallinckrodt CH, Clark SW, Carroll RJ, et al. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat 2003;13:179-90
11. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. Br Med J 1999;319:670-4
12. Moyle GJ. Truth, lies, and statistical tests. AIDS Read 2003;13:117-8, 123-4, 126
13. Wright CC, Sim J. Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis. J Clin Epidemiol 2003;56:833-42
14. Rubin DB. Inference and missing data. Biometrika 1976;63:581-92
15. Gottlieb AB, Hamilton T, Caro I, et al. Long-term continuous efalizumab therapy in patients with moderate to severe chronic plaque psoriasis: updated results from an ongoing trial. J Am Acad Dermatol 2006;54(Suppl 1):S154-S163
16. Hill A, Demasi R. Discordant conclusions from HIV clinical trials - an evaluation of efficacy endpoints. Antiviral Ther 2005;10:367-74
17. Aidsmap forum reports. How to interpret research studies. 2004 [cited February 27, 2006]; Available from: http://www.aidsmap.com/en/docs/02F26BC6- 6841-4612-8647-79D0C10DD043.asp